摘要
目的评价吉西他滨联合氟尿嘧啶(5-Fu)/甲酰四氢叶酸(CF)组成的GLF方案作为二线方案治疗晚期乳腺癌的疗效和毒性。方法38例既往曾接受蒽环类和/或紫杉类方案化疗的晚期乳腺癌患者,采用GLF双周方案,即吉西他滨1,200mg/m2静脉滴注,CF200mg/m2,经静脉滴注5-Fu 325mg/m2,先静脉推注,然后2.8mg/m2持续48h滴注;每2周重复1次,每2次为1周期。结果38例中CR2例、PR14例、NC13例、PD9例,总有效率为42.1%。Ⅲ～Ⅳ度白细胞下降为18.42%,Ⅲ度血小板下降为7.91%,Ⅲ度粒膜炎10.5%,其他不良反应轻微。结论吉西他滨联合5-Fu及CF组成GLF双周方案作为二线方案对蒽环类和/或紫杉类方案耐药的晚期乳腺癌疗效令人满意,不良反应少,值得进一步研究。
Objective To evaluate the efficacy and toxicity ofgemcitabine plus 5-fluorouracil/leucovorin in the treatment of advanced breast caiacer resistant to anthracyclines and/or taxanes.Methods Thirty eight cases of advanced breast cancer pretreated with anthracyclines and/or taxanes were enrolled into this study,Gemcitabine 1200mg/m^2 iv,combined with leucovorin 200mg/m^2 iv,then 10 minutes,intravenous bolus of 5-Fu 325mg/m^2 followed by 48 hours infusion of 5-Fu 2.8g/m^2 using an ambulatory pump.The regimen was given per 14 days. One cycle consisted of twice chemotherapy regimens.All enrolled patients received at least two cycle of treatment. Results CR 2 cases, PR 14 cases, NC 13 cases;PD 9 cases an overall respons rate of 42.1%.The main side effect included grade Ⅲ - Ⅳ leckopenia 18.4%, grade Ⅲ thrombocytopenia 5.9%.Conclusion Gemcitabine plus 5-fluorouracil/leucovorin GLF regimen is effective for advanced breast cancer resistant to anthracyclines and/ or taxcines.
出处
《中国血液流变学杂志》
CAS
2007年第4期594-595,614,共3页
Chinese Journal of Hemorheology
关键词
乳腺癌
联合用药
吉西他滨
breast cancer
combined therapy
Gemcitabine
